drugset / Trial / NCT02170077

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

NCT02170077

Phase 2 Completed 144 enrolled Bial - Portela C S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of BIA 2 093 in the treatment of epileptic patients with refractory simple or complex partial seizures with or without secondary generalization.

Timeline

Start
2002-04
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg Oral

Indications